228 related articles for article (PubMed ID: 35061886)
1. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
Brown LM; Hediyeh-Zadeh S; Sadras T; Huckstep H; Sandow JJ; Bartolo RC; Kosasih HJ; Davidson NM; Schmidt B; Bjelosevic S; Johnstone R; Webb AI; Khaw SL; Oshlack A; Davis MJ; Ekert PG
Blood Adv; 2022 Apr; 6(7):2373-2387. PubMed ID: 35061886
[TBL] [Abstract][Full Text] [Related]
2. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
5. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
Hsieh MY; Van Etten RA
Blood; 2014 Apr; 123(15):2401-11. PubMed ID: 24464015
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
7. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
8. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
9. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
[TBL] [Abstract][Full Text] [Related]
11. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
12. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
[TBL] [Abstract][Full Text] [Related]
13. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
15. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
Hiroki H; Akahane K; Inukai T; Morio T; Takagi M
Int J Hematol; 2023 May; 117(5):748-758. PubMed ID: 36575328
[TBL] [Abstract][Full Text] [Related]
18. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
19. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
20. A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
Kato K; Takagi S; Takano H; Tsunoda S; Watanabe O; Yamaguchi K; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Yamamoto H; Yamamoto G; Asano-Mori Y; Koike Y; Makino S; Wake A; Taniguchi S; Uchida N
Int J Hematol; 2024 Feb; 119(2):205-209. PubMed ID: 38236369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]